SCHEMBL3279396

SCHEMBL3279396

CC1=[C]C(C)=CCS1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12179431 0.66
SCHEMBL21648156 0.54
SCHEMBL895220 0.46
SCHEMBL8758 0.46
SCHEMBL19280 0.45
SCHEMBL12344959 0.43 ACHE (0.91)
O-Xylene SCHEMBL8216257 0.43 TSHR (1.00)
O-Xylene SCHEMBL11034038 0.43 TSHR (1.00)
O-Xylene SCHEMBL170581 0.43 TSHR (1.00)
O-Xylene SCHEMBL10522915 0.43 TSHR (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000900-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein ASTEX PHARMACEUTICALS INC (US) 2022-01-06 US disclosed
US-10941399-B2 Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2021-03-09 US disclosed
US-10933079-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein ASTEX PHARMACEUTICALS, INC. (US) 2021-03-02 US disclosed
US-20200215092-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein ASTEX PHARMACEUTICALS, INC. 2020-07-09 US disclosed
US-20200063130-A1 CHIMERIC RNA OLIGONUCLEOTIDES AND USES THEREOF Università Cattolica del Sacro Cuore (IT) 2020-02-27 US disclosed
US-10456415-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein ASTEX PHARMACEUTICALS, INC. (US) 2019-10-29 US disclosed
US-20170035794-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein ASTEX PHARMACEUTICALS, INC. 2017-02-09 US disclosed
US-9480698-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein ASTEX PHARMACEUTICALS, INC. (US) 2016-11-01 US disclosed
US-9358248-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein ASTEX PHARMACEUTICALS, INC. (US) 2016-06-07 US disclosed
US-20160130296-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein ASTEX PHARMACEUTICALS, INC. 2016-05-12 US disclosed
EP-1943264-B1 OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN ASTEX PHARMACEUTICALS INC (US) 2015-07-29 EP disclosed
US-20140171492-A1 CHIMERIC RNA OLIGONUCLEOTIDES AND USES THEREOF UNIVERSITA CATTOLICA DEL SACRO CUORE (IT) 2014-06-19 US disclosed
US-20130236536-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein ASTEX PHARMACEUTICALS, INC. (US) 2013-09-12 US disclosed
US-8461123-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein ASTEX PHARMACEUTICALS, INC. (US) 2013-06-11 US disclosed
WO-2012142480-A1 CHIMERIC RNA OLIGONUCLEOTIDES AND USES THEREOF BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2012-10-18 WO disclosed
US-20100215729-A1 OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN SUPERGEN, INC. 2010-08-26 US disclosed
US-7700567-B2 methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders SUPERGEN, INC. (US) 2010-04-20 US disclosed
EP-1943264-A2 OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN SuperGen, Inc. (US) 2008-07-16 EP disclosed
WO-2007041071-A2 OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN SUPERGEN, INC. (US) 2007-04-12 WO disclosed
US-20070072796-A1 methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders ASTEX PHARMACEUTICALS, INC. 2007-03-29 US disclosed